Related Experiment Videos
Myeloperoxidase deficient polymorphonuclear leucocytes in leukaemia and allied disorders
1Department of Pathology, Arhus Amtssygehus, Denmark.
Abstract:
This thesis is a survey of nine previously published articles on MPO deficient PMN. The incidences in leukaemia and allied disorders of the presence of this abnormal subpopulation of mature neutrophils and the relationship to clinical course in AML, susceptibility to infections in AML, FAB classification in AML and MDS, cytogenetically defined aberrations in MDS and morphometrical characteristics were investigated. The aims of the studies were to examine the diagnostic as well as the prognostic value of the parameter, to examine the usefulness of the parameter as an predictive indicator of CR and relapse in AML and to examine the concept that MPO deficient PMN may originate from leukaemic precursors. MPO deficient PMN were found to occur in a minor number (less than 4% of the total number of PMN) in normal humans and the incidences of an abnormal number (greater than 4%) were found to be about 40% in AML (I, II, III, IV, VIII), 60% in CML (I, VII), 30% in MPD other than CML (VII) and 30% in MDS (V). The highest incidences in AML were found in the FAB subtypes possessing the most myeloid differentiation potential i.e. FAB M2 and FAB M4 (IV). In ALL, CLL, HCL, Hodgkin's disease, anaemia not related to leukaemia and leukaemoid reactions the incidences all were 0% (I, unpublished data). The abnormal MPO deficient PMN subpopulation, if present, disappeared when CR was achieved and reappeared when relapse eventually was developed (II, VIII). In both situations serial determinations showed that the change occurred before the usual routine blood examinations predicted CR and relapse; several days and several months prior, respectively (VIII). The probability of obtaining CR was lower in the AML patients with the abnormal subpopulation and the risk of developing relapse higher than in AML patients without the anomaly (II, VIII). These differences were not statistically significant, however. AML patients, showing an increased number of MPO deficient PMN, revealed a statistically significant increased susceptibility to infections (P less than 0.01) during the preremission phase accounting for 18% to 67% of the total number of infections in this period (III). This increase was positively correlated to the extent of the anomaly (P less than 0.002). The spontaneous occurrence of a subpopulation of MPO deficient PMN in MDS went together with a simultaneous progression in cytogenetically determined clonal chromosomal aberrations and were related to progression in FAB subtype as well (VI). Morphometrically MPO deficient PMN were characterized by a decreased total cell size and an increased nucleus size of the projected images (IX).(ABSTRACT TRUNCATED AT 400 WORDS)
Insights
Myeloperoxidase (MPO) deficient neutrophils indicate higher infection risk and potential relapse in acute myeloid leukemia (AML) patients. Early detection of MPO deficient PMN may predict remission and relapse before standard diagnostics.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Myeloperoxidase (MPO) deficient polymorphonuclear neutrophils (PMN) are an abnormal subpopulation.
- Their presence and clinical significance in hematological disorders are not fully understood.
Purpose of the Study:
- To investigate the diagnostic and prognostic value of MPO deficient PMN.
- To assess their role as predictive indicators for complete remission (CR) and relapse in acute myeloid leukemia (AML).
- To explore the origin of MPO deficient PMN from leukemic precursors.
Main Methods:
- Literature review of nine published articles.
- Analysis of MPO deficient PMN incidence in various hematological malignancies (AML, CML, MDS, ALL, CLL, etc.).
- Correlation of MPO deficient PMN with clinical course, infection susceptibility, FAB classification, cytogenetic aberrations, and morphometric characteristics.
Main Results:
- Abnormal MPO deficient PMN ( >4%) found in ~40% of AML, 60% of CML, and 30% of MDS patients.
- Incidence was 0% in ALL, CLL, and other non-leukemic conditions.
- MPO deficient PMN disappeared upon CR and reappeared with relapse in AML, preceding routine diagnostics.
- Increased MPO deficient PMN correlated with higher infection susceptibility in AML (P < 0.01).
- In MDS, MPO deficient PMN coincided with chromosomal aberrations and FAB subtype progression.
Conclusions:
- MPO deficient PMN subpopulation has diagnostic and prognostic implications in AML and MDS.
- It serves as a potential early indicator for remission and relapse in AML.
- Increased MPO deficient PMN is linked to heightened infection risk in AML patients.
- Further research is warranted to understand the origin and precise role of MPO deficient PMN.